


Substitute for form 1449/PTO

Complete if Known

| | |
|------------------------|--------------------------|
| Application Number | 10/765,227 |
| Filing Date | January 26, 2004 |
| First Named Inventor | Atsuo Kuki |
| Art Unit | To be assigned - 1626 |
| Examiner Name | To be assigned - Anthony |
| Attorney Docket Number | PC25051A Parighanath |

**U.S. PATENT DOCUMENTS**

| EXAMINER INITIAL | Cite No. ¹ | DOCUMENT NUMBER Number-Kind Code ² | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|------------------|-----------------------|--|--------------------------------|---|---|
| ASP | AA | 10/699,068 | Filed on 10-30-2003 | Agouron Pharmaceuticals, Inc. | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | Cite No. ¹ | Foreign Patent Document Country Code ² Number ³ Kind Code ⁵ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|------------------|-----------------------|--|--------------------------------|--|---|----------------|
| ASP | AB | WO 02/070491 (English abstract enclosed) | 09-12-2002 | Abstract only Shionogi & Co., Ltd. | | |
| ASP | AC | JP 2003119137 (English abstract enclosed) | 04-23-2003 | Abstract only Japan Tobacco, Inc. | | |
| ASP | AD | WO 03/035076 | 05-01-2003 | Instituto Di Richerche Di Biologa Molecolare P. Angeletti Spa Di Francesco | | |
| ASP | AE | WO 03/047564 (English abstract enclosed) | 06-12-2003 | Abstract only Shionogi & Co., Ltd. | | |
| ASP | AF | WO 03/049690 | 06-19-2003 | Bristol-Myers Squibb Company Walker | | |

EXAMINER:

DATE CONSIDERED:

3/14/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|------------------------|
| Application Number | 10/765,227 |
| Filing Date | January 26, 2004 |
| First Named Inventor | Atsuo Kuki |
| Art Unit | To be assigned 1626 |
| Examiner Name | To be assigned Anthony |
| Attorney Docket Number | PC25051A Carlight |

| | | | | | |
|-----|----|---|------------|--|--|
| ATP | AG | JP 2003171381 (counterpart is WO 2003035650 for which English abstract is enclosed) | 06-20-2003 | Abstract only Takeda Chemical Industries, Ltd. | |
| ATP | AH | WO 03/062204 | 07-31-2003 | Merck & Co., Inc. Egbertson | |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|----------------------|--------------------------|---|----------------|
| ATP | AI | ABDEL-MAGID, et al., "Reductive Amination of Aldehydes And Ketones With Sodium Triacetoxymethylborohydride. Studies On Direct And Indirect Reductive Amination Procedures," <i>Journal of Organic Chemistry</i> , 1996, 3849-3862, Vol. 61. | |
| ATP | AJ | BAGSHAWE, K. et. al., "Antibody-Directed Enzyme Prodrug Therapy: A Review," <i>Drug Development Research</i> , 1995, 220-230, Vol. 34. | |
| ATP | AK | BARBIER, C., et al., "Preparation of Lavendamycin Analogues," <i>Heterocycles</i> , 2000, 37-48, Vol. 53, No. 1. | |
| ATP | AL | BERTOLINI, G. et. al., "A New Rational Hypothesis for the Pharmacophore of the Active Metabolite of Leflunomide, a Potent Immunosuppressive Drug," <i>J. Med. Chem.</i> , 1997, 2011-2016, Vol. 40. | |
| ATP | AM | BIERE, H., et al., "Eine Neue und Besonders Einfache Synthese Von Zentralaktiven β -Carbolin-Derivaten," <i>Liebigs Ann. Chem.</i> , 1986, 1749-1764 (see English abstract). | |
| ATP | AN | BODOR, N., "Novel Approaches to the Design of Safer Drugs: Soft Drugs and Site-Specific Chemical Delivery Systems," <i>Advances in Drug Research</i> , 1984, 255-331, Vol. 13. | |
| ATP | AO | BUNDGAARD, et al., <i>Design of Prodrugs</i> , 1985, Elsevier Press. (table of contents only) | |
| ATP | AP | BUNDGAARD, H. "Design and Application of Prodrugs", <i>Drug Design Application and Development</i> , 1991. | |
| ATP | AQ | BUTLER, S.L., et al., "A Quantitative Assay for HIV DNA Integration <i>In Vivo</i> ," <i>Nature Medicine</i> , May 2001, 631-634, Vol. 7, No. 5. | |
| ATP | AR | CAMPBELL, K.N., et al., "The Preparation of Unsymmetrical Secondary Aliphatic Amines," <i>J. Am. Chem. Soc.</i> , 1944, 82-84, Vol. 66. | |

EXAMINER:

DATE CONSIDERED:

3/14/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|----------------------------|
| Application Number | 10/765,227 |
| Filing Date | January 26, 2004 |
| First Named Inventor | Atsuo Kuki |
| Art Unit | To be assigned 1626 |
| Examiner Name | To be assigned A. Periglas |
| Attorney Docket Number | PC25051A |

| | | | |
|-----|----|--|--|
| AJP | AS | CHEN, B. et al., "Distinct Modes Of Human Immunodeficiency Virus Type 1 Proviral Latency Revealed By Superinfection Of Nonproductively Infected Cell Lines With Recombinant Luciferase-Encoding Viruses," <i>Journal of Virology</i> , 1994, 654-660, Vol. 68, No. 2. <i>abstract only</i> | |
| AJP | AT | DEAR, G.J. et al., "Mass Directed Peak Selection, an Efficient Method of Drug Metabolite Identification Using Directly Coupled Liquid Chromatography-Mass Spectrometry-Nuclear Magnetic Resonance Spectroscopy," <i>Journal of Chromatography B</i> , 2000, 281-293, Vol. 748. | |
| AJP | AU | DEBYSER, Z., et al., "Assays for the Evaluation of HIV-1 Integrase Inhibitors," <i>Methods in Molecular Biology</i> 160, 139-155. SCHEIN, C.H., Humana Press Inc., Totawa, NJ 2001. | |
| AJP | AV | DEKHANE, M., et al., "A New Efficient Synthesis of Ethyl β -Carboline-3-Carboxylate (β -CCE) and Methyl 4-Methyl- β -Carboline-3-Carboxylate (4-Methyl- β -CCM) Starting From Indole-2 Carboxaldehyde," <i>Tetrahedron</i> , 1994, 6299-6306, Vol. 50, No. 21. | |
| AJP | AW | DOYLE, et al., "Nuclear Analogs of β -lactam Antibiotics. I. Synthesis of O-2-isocephams," <i>Can. J. Chem.</i> , 1977, 468-483, Vol. 55. | |
| AJP | AX | EBERLE, M., "Contribution To The Chemistry Of Indole. About The 5-(1-Indolyl)-2-Pentanone System," <i>Journal of Organic Chemistry</i> , 1976, 633-636, Vol. 41, No. 4. | |
| AJP | AY | ELIEL, E.L., et al., <i>Stereochemistry of Organic Compounds</i> , Wiley, New York, 1994. <i>table of contents only</i> | |
| AJP | AZ | EROFEEV, Y.V., et al., "Introduction of 3-Indolymethyl Residues in Nitroacetic Acid Esters," <i>Khim. Get. Soed.</i> , 1978, 780. | |
| AJP | BA | GOLDGUR, Y., et al., "Structure Of The HIV-1 Integrase Catalytic Domain Complexed With An Inhibitor: A Platform For Antiviral Drug Design," <i>PNAS</i> , November 9, 1999, 13040-13043, Vol. 96, No. 23. | |
| AJP | BB | GROBLER, J. et al., "Diketo Acid Inhibitor Mechanism And HIV-1 Integrase: Implications For Metal Binding In The Active Site Of Phosphotransferase Enzymes," <i>PNAS</i> , May 14, 2002, 6661-6666, Vol. 99, No. 10. | |
| AJP | BC | HANSEN, M.S., et al., "Integration Complexes Derived From HIV Vectors For Rapid Assays In Vitro," <i>Nature Biotechnology</i> , June 1999, 578-582, Vol. 17, No. 6. | |
| AJP | BD | HAUSER, C.R., et al., <i>Org. Synth. Coll.</i> , Vol. 2., 1943, 67, John Wiley, New York. <i>table of contents only</i> | |
| AJP | BE | HAZUDA, D. et al., "Discovery And Analysis Of Inhibitors Of The Human Immunodeficiency Integrase," <i>Drug Design And Discovery</i> , 1997, 17-24, Vol. 15. | |

EXAMINER:

DATE CONSIDERED:

3/17/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)**Complete if Known**

| | |
|------------------------|------------------------------|
| Application Number | 10765,227 |
| Filing Date | January 26, 2004 |
| First Named Inventor | Atsuo Kuki |
| Art Unit | To be assigned 1626 |
| Examiner Name | To be assigned A Kelly Searf |
| Attorney Docket Number | PC25051A |

| | | | |
|-----|----|---|--|
| ATP | BF | JENKINS, T.M., et al., "A Soluble Active Mutant of HIV-1 Integrase," <i>Journal of Biological Chemistry</i> , 1996, 7712-7718, Vol. 271, No. 13. | |
| ATP | BG | KANTLEHNER, W., et al., "Umsetzungen von <i>tert</i> -Butoxy-N,N,N',N'-tetramethylmethandiamin mit Nh- und CH-aciden Verbindungen," <i>Liebigs Ann. Chem.</i> , 1980, 344 (see English abstract). | |
| ATP | BH | LEWIN, S.R., et al., "Use of Real-Time PCR and Molecular Beacons to Detect Virus Replication in Human Immunodeficiency Virus Type 1-Infected Individuals on Prolonged Effective Antiretroviral Therapy," <i>Journal of Virology</i> , July 1999, 6099-6103, Vol. 73, No. 7. | |
| ATP | BI | LYTTLE, D.A., et al., "The Chemistry of Nitroacetic Acid and Its Esters. I. The Alkylation of Alkyl/nitroacetates with Gramine," <i>J. Am. Chem. Soc.</i> , 1947, 2118-2119, Vol. 69. | |
| ATP | BJ | MARCH, JERRY, <i>Advanced Organic Chemistry</i> , 5 th Edition, 508, 511, John Wiley & Sons, 2001. <i>(table of contents only)</i> | |
| ATP | BK | NEEF, G., et al., "Synthesis of 4-Substituted β -Carbolines," <i>Heterocycles</i> , 1983, 1295-1313, Vol. 20, No. 7. | |
| ATP | BL | PAIS, G., et al., "Structure Activity of 3-Aryl-1,3-diketo-Containing Compounds as HIV-1 Integrase Inhibitors," <i>Journal of Medicinal Chemistry</i> , 2002, pp. 3184-3194, Vol. 45. | |
| ATP | BM | PROX, et al., "Rapid Structure Elucidation of Drug Metabolites by Use of Stable Isotopes," <i>Xenobiotica</i> , 1973, 103-112, Vol. 3 No. 2. | |
| ATP | BN | SANDRIN, J., et al., "Pictet-Spengler Condensations in Refluxing Benzene," <i>Heterocycles</i> , 1976, 1101-1104, Vol. 4, No. 6. | |
| ATP | BO | SAYASITH, K., et al., "Targeting HIV-1 Integrase," <i>Expert Opin. Ther. Targets</i> , 2001, 443-464, Vol. 5, No. 4. | |
| ATP | BP | SETTIMJ, et al., " β -Carbolines as Agonistic or Antagonistic Benzodiazepine Receptor Ligands. 1. Synthesis of some 5-, 6- and 7-Amino Derivatives of 3-Methoxycarbonyl- β -carboline (β -CCM) and of 3-Ethoxycarbonyl- β -Carboline (β -CCE)," <i>J. Heterocycl. Chem.</i> , 1988, 1391-1397, Vol. 25. | |
| ATP | BQ | SHAN, D. et al., "Prodrug Strategies Based On Intramolecular Cyclization Reactions," <i>J. Pharm. Sci.</i> , 1997, 765-767, Vol. 86, No. 7. | |
| ATP | BR | SNYDER, H.R., et al., "The Synthesis of the 2-Amino-3-(3-indolyl)-butyric Acids (β -Methyltryptophans)," <i>J. Am. Chem. Soc.</i> , 1957, 2217-2221, Vol. 79. | |
| ATP | BS | SPRAUL, et al., "Liquid Chromatography Coupled with High-Field Proton NMR for Profiling Human Urine for Endogenous Compounds and Drug Metabolites," <i>J. Pharmaceutical & Biomedical Analysis</i> , 1992, 601-605, Vol. 10, No. 8. | |

EXAMINER:

DATE CONSIDERED:

3/14/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)**Complete if Known**

| | |
|------------------------|--------------------------------|
| Application Number | 10/765,227 |
| Filing Date | January 26, 2004 |
| First Named Inventor | Atsuo Kuki |
| Art Unit | To be assigned 1626 |
| Examiner Name | To be assigned A. H. [unclear] |
| Attorney Docket Number | PC25051A |

| | | | |
|-----|----|---|--|
| ATP | BT | STILL, W., et al., "Rapid Chromatographic Technique For Preparative Separations With Moderate Resolution," <i>Journal of Organic Chemistry</i> , 1978, 2923-2925, Vol. 43, No. 14. | |
| ATP | BU | SUNDBERG, et al., "Syntheses With N-Protected 2-Lithioindoles," <i>Journal of Organic Chemistry</i> , 1973, 3324-3330, Vol. 38, No. 19. | |
| ATP | BV | TERWILLIGER, E.F., et al., "Construction and Use of a Replication-Competent Human Immunodeficiency Virus (HIV-1) That Expresses the Chloramphenicol acetyltransferase Enzyme," <i>Proc. Natl. Acad. Sci., USA</i> , May 1989, 3857-3861, Vol. 86. | |
| ATP | BW | WAI, J. et al., "4-Aryl-2,4-Dioxobutanoic Acid Inhibitors Of HIV-1 Integrase And Viral Replication In Cells," <i>Journal of Medicinal Chemistry</i> , December 28, 2000, 4923-4926, Vol. 43, No. 26. | |
| ATP | BX | WEISLOW, O.S., et al., "New Soluble-Formazan Assay for HIV-1 Cytopathic Effects: Application to High-Flux Screening of Synthetic and Natural Products for AIDS-Antiviral Activity," <i>J. Natl. Cancer Inst.</i> , April 19, 1989, 577-586, Vol. 81, No. 8. | |
| ATP | BY | YOUNG, S.D., et al., "Inhibition of HIV-1 Integrase by Small Molecules: The Potential for a New Class of AIDS Chemotherapeutics," <i>Curr. Opin. Drug Disc. & Devel.</i> , 2001, 402-410, Vol. 4, No. 4. | |
| ATP | BZ | YOUNG, S., et al., "L-870, 810: A Potent Antiviral HIV Integrase Inhibitor with Potential Clinical Utility," Poster presented at International AIDS Conference, Barcelona, (July 7-12, 2002). | |
| | | | |

EXAMINER:

DATE CONSIDERED:

3/14/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). **See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|------------------------------|
| Application Number | 10/765,227 |
| Filing Date | 01/26/2004 |
| First Named Inventor | Atsuo KUKI |
| Art Unit | 4720-1626 |
| Examiner Name | Not yet assigned A. Paraglin |
| Attorney Docket Number | PC25051A |

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | Cite No. ¹ | DOCUMENT NUMBER | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|---------------------|--------------------------|-------------------------------|--------------------------------|--|--|
| | | Number-Kind Code ² | | | |
| | | | | | |
| | | | | | |
| | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ³ |
|---------------------|--------------------------|--|-----------------------------------|--|---|----------------|
| | | Country Code ² Number ² Kind Code ² (if known) | | | | |
| ATP | AA | WO 03/033496 A | 04.24.2003 | Adnan M. MJALLI, et al. | | |
| ATP | AB | WO 99/64420 | 12.16.1999 | Christophe ALAIN, et al. | (English counterpart to EP1086101). | |
| ATP | AC | EP 0 030 254 A | 08.23.1980 | Dr. Ulrich, EDER, et al. | | |
| ATP | AD | GB 2 209 032 A | 04.26.1989 | Charles John Robert HEDGECOCK, et al | | |
| ATP | AE | EP 1 209 158 A | 11.18.2000 | Dr. Olaf RITZELER, et al. | | |

EXAMINER:

DATE CONSIDERED:

3/14/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Information Disclosure Statement

Page 1 of 1

ATP

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO



INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|--------------------------------|
| Application Number | 10765,227 |
| Filing Date | 01/26/2004 |
| First Named Inventor | Atsuo Kuki |
| Art Unit | 4720-1626 |
| Examiner Name | Not yet assigned - A. Roughton |
| Attorney Docket Number | PC25051A |

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | Cite No. ¹ | DOCUMENT NUMBER Number-Kind Code ² | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|------------------|-----------------------|--|--------------------------------|---|---|
| | | | | | |
| | | | | | |
| | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | Cite No. ¹ | Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|------------------|-----------------------|--|--------------------------------|---|---|----------------|
| KJP | AA | EP 1 086 101 B1 | 03-28-2001 | Societe De Conseils De Recherches <i>Pharm 1894</i> | | |
| | | | | | | |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|-------------------|-----------------------|---|----------------|
| | | | |
| | | | |
| | | | |
| | | | |

EXAMINER:

Anthony J. Galt

DATE CONSIDERED:

3/14/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.